ym 529 has been researched along with B16 Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Itoh, T; Kaneko, J; Kidera, Y; Nishida, S; Satou, T; Tanimori, Y; Tsubaki, M; Yamamoto, C; Yamazoe, Y; Yanae, M | 1 |
| Abe, R; Bucala, R; Imaizumi, T; Inagaki, Y; Inokuma, D; Nakamura, H; Nakamura, K; Shimizu, H; Shimizu, T; Sugawara, H; Takeuchi, M; Yamagishi, S; Yoshimura, A | 1 |
2 other study(ies) available for ym 529 and B16 Melanoma
| Article | Year |
|---|---|
Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway.
Topics: Animals; Base Sequence; Blotting, Western; Cell Line, Tumor; Diphosphonates; DNA Primers; Female; Imidazoles; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Polymerase Chain Reaction; rho-Associated Kinases | 2010 |
Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.
Topics: Animals; Apoptosis; Cell Adhesion; Diphosphonates; DNA; Endothelium, Vascular; Female; Humans; Imidazoles; Melanoma, Experimental; Mice; Mice, Nude; NADPH Oxidases; Neovascularization, Pathologic; rac1 GTP-Binding Protein; Reactive Oxygen Species; Signal Transduction; Skin Neoplasms; Survival Rate; Vascular Endothelial Growth Factor A | 2004 |